Get started
Author

Eduardo Ramacciotti

Observed names: E Ramacciotti, E. RAMACCIOTTI, E. Ramacciotti, EDUARDO RAMACCIOTTI, Eduardo Costa Ramacciotti, Eduardo RAMACCIOTTI, Ramacciotti, Eduardo
Observed institutions: Loyola University Medical Center, Regenstrief Institute, Universidade de São Paulo, Pfizer (United States), Loyola University Chicago, Princeton University, Cornell University, University of Michigan, Hospital Israelita Albert Einstein, Irmandade da Santa Casa de Misericórdia de São Paulo, Bristol-Myers Squibb (United States), Centro Universitário de Várzea Grande, Hospital Leforte, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Michigan Medicine, Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics, Loyola Medicine, Weill Cornell Medicine, Indiana University Indianapolis, Indiana University School of Medicine, Indiana University, Universidade Federal de Goiás, Tehran University of Medical Sciences, Universidade Federal de São Paulo
ORCID: 0000-0002-5735-1333
Observed ORCID: 0000-0002-5735-1333
OpenAlex ID: A5075481121
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
2021 · Renato D Lopes, Pedro Gabriel Melo de Barros e Silva, et al. · The Lancet · 488
PDF
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19
2022 · Anil Gupta, Yaneicy Gonzalez-Rojas, et al. · JAMA · 277
PDF
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
2021 · Eduardo Ramacciotti, Leandro Barile Agati, et al. · The Lancet · 255
PDF
ISTH guidelines for antithrombotic treatment in COVID‐19
2022 · Sam Schulman, Michelle Sholzberg, et al. · Journal of Thrombosis and Haemostasis · 191
Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants
2012 · D. GARCIA, Y.C. BARRETT, et al. · Journal of Thrombosis and Haemostasis · 120
Vein Imaging
2006 · ROBERTO KASUO MIYAKE, HERBERT DAVID ZEMAN, et al. · Dermatologic Surgery · 116
Evaluation of Soluble P-Selectin as a Marker for the Diagnosis of Deep Venous Thrombosis
2011 · Eduardo Ramacciotti, Susan Blackburn, et al. · Clinical and Applied Thrombosis/Hemostasis · 105
Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis
2009 · Angela Hawley, Diana Farris, et al. · Thrombosis and Haemostasis · 97
PDF
Proteomics of microparticles after deep venous thrombosis
2010 · Eduardo Ramacciotti, Angela E. Hawley, et al. · Thrombosis Research · 77
Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence
2024 · Andrew N. NICOLAIDES, Jawed FAREED, et al. · International Angiology · 71
Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy
2020 · Fernanda Andrade Orsi, Erich V. De Paula, et al. · Hematology Transfusion and Cell Therapy · 56
Chemically Oversulfated Glycosaminoglycans Are Potent Modulators of Contact System Activation and Different Cell Signaling Pathways
2010 · Jing Pan, Yi Qian, et al. · Journal of Biological Chemistry · 56
PDF
Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis
2003 · Eduardo Ramacciotti, Nelson Wolosker, et al. · Thrombosis Research · 56
Zika and Chikungunya Virus and Risk for Venous Thromboembolism
2019 · Eduardo Ramacciotti, Leandro B. Agati, et al. · Clinical and Applied Thrombosis/Hemostasis · 52
P-selectin/ PSGL-1 Inhibitors versus enoxaparin in the resolution of venous thrombosis: A meta-analysis
2009 · Eduardo Ramacciotti, Daniel D. Myers, et al. · Thrombosis Research · 52
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
2024 · Sam Schulman, Donald M. Arnold, et al. · Journal of Thrombosis and Haemostasis · 49
An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination
2021 · Bulent Kantarcioglu, Omer Iqbal, et al. · Clinical and Applied Thrombosis/Hemostasis · 45
Drug–Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
2020 · Érique José F. Peixoto de Miranda, Thamy Takahashi, et al. · Clinical and Applied Thrombosis/Hemostasis · 42
Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil
2019 · M. Julia Machline-Carrion, Rafael Marques Soares, et al. · JAMA Cardiology · 41
PDF
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
2019 · Fakiha Siddiqui, Alfonso Tafur, et al. · Clinical and Applied Thrombosis/Hemostasis · 41
Gender-Dependent Differential Phosphorylation in the ERK Signaling Pathway is Associated with Increased MMP2 Activity in Rat Aortic Smooth Muscle Cells
2009 · Lauren K. Ehrlichman, John W. Ford, et al. · Journal of Surgical Research · 41
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model
2017 · Patrick A. Lester, Dawn M. Coleman, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 38
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups
2012 · G.F. PINEO, A.S. GALLUS, et al. · Journal of Thrombosis and Haemostasis · 38
Apixaban: an Oral Direct Factor-Xa Inhibitor
2012 · David Jiménez, Roger D. Yusen, et al. · Advances in Therapy · 38
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial
2022 · André Luiz Malavasi Longo de Oliveira, Renata Fernanda de Oliveira Pereira, et al. · Clinical and Applied Thrombosis/Hemostasis · 36
Works count: 146
Citation count: 3,230
H-index: 30
I10-index: 53
Year
Topic
Type